- Home
- MRNO vs LENZ Comparison
MRNO vs LENZ Comparison
Compare MRNO & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNO
- LENZ
- Stock Information
- Founded
- MRNO 2021
- LENZ 2019
- Country
- MRNO United Kingdom
- LENZ United States
- Employees
- MRNO N/A
- LENZ N/A
- Industry
- MRNO
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- MRNO
- LENZ Health Care
- Exchange
- MRNO NYSE
- LENZ Nasdaq
- Market Cap
- MRNO 794.8M
- LENZ 729.6M
- IPO Year
- MRNO N/A
- LENZ 2021
- Fundamental
- Price
- MRNO $10.47
- LENZ $25.64
- Analyst Decision
- MRNO
- LENZ Strong Buy
- Analyst Count
- MRNO 0
- LENZ 6
- Target Price
- MRNO N/A
- LENZ $38.00
- AVG Volume (30 Days)
- MRNO 4.4K
- LENZ 256.9K
- Earning Date
- MRNO 05-25-2025
- LENZ 03-19-2025
- Dividend Yield
- MRNO N/A
- LENZ N/A
- EPS Growth
- MRNO N/A
- LENZ N/A
- EPS
- MRNO N/A
- LENZ N/A
- Revenue
- MRNO $27,954,510.00
- LENZ N/A
- Revenue This Year
- MRNO N/A
- LENZ N/A
- Revenue Next Year
- MRNO N/A
- LENZ $535.40
- P/E Ratio
- MRNO N/A
- LENZ N/A
- Revenue Growth
- MRNO 211.17
- LENZ N/A
- 52 Week Low
- MRNO $5.70
- LENZ $14.42
- 52 Week High
- MRNO $13.25
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- MRNO 43.42
- LENZ 54.15
- Support Level
- MRNO $10.35
- LENZ $25.17
- Resistance Level
- MRNO $11.94
- LENZ $27.89
- Average True Range (ATR)
- MRNO 0.76
- LENZ 1.79
- MACD
- MRNO -0.05
- LENZ 0.25
- Stochastic Oscillator
- MRNO 10.32
- LENZ 61.47
About MRNO MURANO GLOBAL INVESTMENTS LIMITED
Murano Global Investments PLC is a real estate company that owns, develops, and invests in hotel, resort, and commercial properties throughout Mexico. Its portfolio includes the Andaz and Mondrian Hotels in Mexico City and Vivid Hotel Grand Island. The revenues are derived from the products and services provided to our customers such as Room rentals, Food and beverage, Private events, Spa services, and Other services.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.